购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空
顶部生物活性化学信息储存和溶解信息计算器

AGN-195183

Rating icon 还可以
产品编号 T14144Cas号 367273-07-2

AGN 195183 is a potent and selective agonist of RARα(Kd=3 nM) with improved binding selectivity relative to AGN 193836; no activity on RARβ/γ. IC50 value: 3 nM (Kd); 200 nM (EC80, RAR Trans.) Target: RARα agonist Compound 4(AGN-195183) inhibited the growth of breast cancer cell lines, and was inactive in an in vivo model of topical irritation. Compound 4 (AGN 195183) is currently in Phase I/IIA clinical trials in cancer patients. Compound 4 and ATRA inhibit growth of the human breast cancer cell lines, T-47D and SK-BR-3, however it does not cause the topical irritation induced by the RARa-selective retinoid, Am-580.

AGN-195183
TargetMol

为众多的药物研发团队赋能，

让新药发现更简单！

AGN-195183

Rating icon 还可以
产品编号 T14144Cas号 367273-07-2

AGN 195183 is a potent and selective agonist of RARα(Kd=3 nM) with improved binding selectivity relative to AGN 193836; no activity on RARβ/γ. IC50 value: 3 nM (Kd); 200 nM (EC80, RAR Trans.) Target: RARα agonist Compound 4(AGN-195183) inhibited the growth of breast cancer cell lines, and was inactive in an in vivo model of topical irritation. Compound 4 (AGN 195183) is currently in Phase I/IIA clinical trials in cancer patients. Compound 4 and ATRA inhibit growth of the human breast cancer cell lines, T-47D and SK-BR-3, however it does not cause the topical irritation induced by the RARa-selective retinoid, Am-580.

规格价格库存数量
2 mg¥ 1,4705日内发货
5 mg¥ 2,4905日内发货
25 mg¥ 8,6208-10周
50 mg¥ 11,2008-10周
100 mg¥ 17,4008-10周
1 mL x 10 mM (in DMSO)¥ 2,9705日内发货
大包装 & 定制
加入购物车
TargetMol 的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。
实验操作小课堂
常见问题解答
查看更多
联系我们获取更多批次信息
资源下载
产品操作手册

产品介绍

生物活性
产品描述
AGN 195183 is a potent and selective agonist of RARα(Kd=3 nM) with improved binding selectivity relative to AGN 193836; no activity on RARβ/γ. IC50 value: 3 nM (Kd); 200 nM (EC80, RAR Trans.) Target: RARα agonist Compound 4(AGN-195183) inhibited the growth of breast cancer cell lines, and was inactive in an in vivo model of topical irritation. Compound 4 (AGN 195183) is currently in Phase I/IIA clinical trials in cancer patients. Compound 4 and ATRA inhibit growth of the human breast cancer cell lines, T-47D and SK-BR-3, however it does not cause the topical irritation induced by the RARa-selective retinoid, Am-580.
靶点活性
RARα:3 nM (Kd)
化学信息
分子量437.86
分子式C22H22ClF2NO4
CAS No.367273-07-2
密度1.354 g/cm3 (Predicted)
储存&溶解度
存储Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度信息
DMSO: 62 mg/mL (141.60 mM)
溶液配制表
DMSO
1mg5mg10mg50mg
1 mM2.2838 mL11.4192 mL22.8384 mL114.1918 mL
5 mM0.4568 mL2.2838 mL4.5677 mL22.8384 mL
10 mM0.2284 mL1.1419 mL2.2838 mL11.4192 mL
20 mM0.1142 mL0.5710 mL1.1419 mL5.7096 mL
50 mM0.0457 mL0.2284 mL0.4568 mL2.2838 mL
100 mM0.0228 mL0.1142 mL0.2284 mL1.1419 mL

计算器

  • 摩尔浓度 计算器
  • 稀释 计算器
  • 配液 计算器
  • 分子量 计算器

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算，可以得到母液配置方法和体内配方的制备方法：
TargetMol | Animal experiments比如您的给药剂量是 10 mg/kg ，每只动物体重 20 g ，给药体积 100 μL ， TargetMol | Animal experiments 一共给药动物 10 只 ，您使用的配方为 5% TargetMol | reagent DMSO+ 30%PEG300+ 5%Tween 80 + 60% ddH2O. 那么您的工作液浓度为 2 mg/mL 。
母液配置方法: 2 mg 药物溶于 50 μLDMSOTargetMol | reagent （ 母液浓度为 40 mg/mL ）, 如您需要配置的浓度超过该产品的溶解度，请先与我们联系。
体内配方的制备方法: 取 50μLDMSOTargetMol | reagent 母液，添加 300 μLPEG300TargetMol | reagent 混匀澄清，再加 50μLTween 80, 混匀澄清，再加 600μLddH2OTargetMol | reagent 混匀澄清

以上为“体内实验配液计算器”的使用方法举例，并不是具体某个化合物的推荐配制方式，请根据您的实验动物和给药方式选择适当的溶解方案。

1 请输入动物实验的基本信息
mg/kg
g
μL
2 请输入动物体内配方组成，不同的产品配方组成不同，如有配方需求，可先联系我们提供正确的体内配方。
% DMSO
%
%Tween 80
%ddH2O

剂量转换

对于不同动物的给药剂量换算，您也可以参考 更多

关键词

AGN-195183AGN195183AGN 195183

评论列表

4个月前
5.0
Rating icon 很棒

评论内容

233
Related Tags: buy AGN-195183 | purchase AGN-195183 | AGN-195183 cost | order AGN-195183 | AGN-195183 chemical structure | AGN-195183 formula | AGN-195183 molecular weight
TargetMol | Logo

版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.

沪ICP备20019793号-4沪公网安备 31010602006700号TargetMol | Copyright